Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
22nd Century ( (XXII) ) has provided an announcement.
On September 18, 2025, 22nd Century Group, Inc. announced the full repayment of its senior secured debt, totaling $3.9 million, which was completed ahead of its maturity date. This financial move, following the closing of its Series A convertible preferred stock offering, results in a debt-free balance sheet and positions the company for growth by reducing ongoing cash needs and operating costs. The company plans to use its improved financial position to expand its inventory of very low nicotine tobacco leaf, supporting the production of over one million cartons of VLN products, and to focus on the growth of its branded products and intellectual property portfolio.
The most recent analyst rating on (XXII) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on 22nd Century stock, see the XXII Stock Forecast page.
Spark’s Take on XXII Stock
According to Spark, TipRanks’ AI Analyst, XXII is a Underperform.
22nd Century’s overall stock score is primarily impacted by its weak financial performance, characterized by negative margins, high leverage, and cash flow challenges. Technical analysis also indicates a bearish trend, further weighing on the score. While there are strategic shifts and corporate developments that could improve future prospects, the current financial and market conditions present significant risks.
To see Spark’s full report on XXII stock, click here.
More about 22nd Century
22nd Century Group, Inc. is a pioneering company in the tobacco industry, focusing on tobacco harm reduction through its proprietary non-GMO reduced nicotine tobacco plants. The company has developed a flagship product, the VLN® cigarette, which contains 95% less nicotine than traditional cigarettes and is the only low nicotine combustible cigarette authorized by the FDA in the United States.
Average Trading Volume: 993,019
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.58M
For an in-depth examination of XXII stock, go to TipRanks’ Overview page.